<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Rheumatology Study Guide</title>
    <style>
        * {
            box-sizing: border-box;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif;
            line-height: 1.6;
            color: #24292e;
            max-width: 1000px;
            margin: 0 auto;
            padding: 20px;
            background: #fff;
        }
        
        h1 {
            color: #6f42c1;
            border-bottom: 3px solid #6f42c1;
            padding-bottom: 10px;
            font-size: 28px;
        }
        
        h2 {
            color: #6f42c1;
            border-bottom: 2px solid #e1e4e8;
            padding-bottom: 8px;
            margin-top: 40px;
            font-size: 22px;
        }
        
        h3 {
            color: #24292e;
            margin-top: 25px;
            font-size: 18px;
            border-left: 4px solid #6f42c1;
            padding-left: 12px;
        }
        
        h4 {
            color: #586069;
            margin-top: 20px;
            font-size: 16px;
        }
        
        .header-box {
            background: linear-gradient(135deg, #6f42c1 0%, #8b5cf6 100%);
            color: white;
            padding: 30px;
            border-radius: 12px;
            margin-bottom: 30px;
            text-align: center;
        }
        
        .header-box h1 {
            color: white;
            border: none;
            margin: 0;
            font-size: 32px;
        }
        
        .header-box .subtitle {
            font-size: 16px;
            opacity: 0.9;
            margin-top: 8px;
        }
        
        .toc {
            background: #f6f8fa;
            padding: 20px 25px;
            border-radius: 8px;
            margin-bottom: 30px;
        }
        
        .toc h2 {
            margin-top: 0;
            font-size: 18px;
            border: none;
        }
        
        .toc-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(280px, 1fr));
            gap: 8px;
        }
        
        .toc a {
            color: #6f42c1;
            text-decoration: none;
            display: block;
            padding: 4px 0;
        }
        
        .toc a:hover {
            text-decoration: underline;
        }
        
        .section {
            margin-bottom: 40px;
            padding: 25px;
            background: #fafbfc;
            border-radius: 8px;
            border-left: 4px solid #6f42c1;
        }
        
        .section h2 {
            margin-top: 0;
        }
        
        .highlight-box {
            background: #fff3cd;
            border: 1px solid #ffc107;
            border-radius: 6px;
            padding: 15px;
            margin: 15px 0;
        }
        
        .pearl-box {
            background: #e8f4fd;
            border: 1px solid #0366d6;
            border-radius: 6px;
            padding: 15px;
            margin: 15px 0;
        }
        
        .pearl-box::before {
            content: "üíé Clinical Pearl: ";
            font-weight: bold;
            color: #0366d6;
        }
        
        .emergency-box {
            background: #fee2e2;
            border: 1px solid #dc2626;
            border-radius: 6px;
            padding: 15px;
            margin: 15px 0;
        }
        
        .emergency-box::before {
            content: "üö® Emergency: ";
            font-weight: bold;
            color: #dc2626;
        }
        
        .mnemonic-box {
            background: #f0fdf4;
            border: 1px solid #22c55e;
            border-radius: 6px;
            padding: 15px;
            margin: 15px 0;
        }
        
        .mnemonic-box::before {
            content: "üìù Mnemonic: ";
            font-weight: bold;
            color: #22c55e;
        }
        
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 15px 0;
            font-size: 14px;
        }
        
        th, td {
            border: 1px solid #e1e4e8;
            padding: 10px 12px;
            text-align: left;
        }
        
        th {
            background: #6f42c1;
            color: white;
            font-weight: 600;
        }
        
        tr:nth-child(even) {
            background: #f6f8fa;
        }
        
        ul, ol {
            margin: 10px 0;
            padding-left: 25px;
        }
        
        li {
            margin: 6px 0;
        }
        
        .drug-box {
            background: #fdf4ff;
            border: 1px solid #a855f7;
            border-radius: 6px;
            padding: 15px;
            margin: 15px 0;
        }
        
        .criteria-box {
            background: #f8fafc;
            border: 2px solid #6f42c1;
            border-radius: 8px;
            padding: 20px;
            margin: 20px 0;
        }
        
        .criteria-box h4 {
            margin-top: 0;
            color: #6f42c1;
        }
        
        code {
            background: #f1f5f9;
            padding: 2px 6px;
            border-radius: 4px;
            font-family: "SF Mono", Monaco, monospace;
            font-size: 13px;
        }
        
        .trial-link {
            color: #6f42c1;
            text-decoration: none;
        }
        
        .trial-link:hover {
            text-decoration: underline;
        }
        
        .two-column {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 20px;
        }
        
        @media (max-width: 768px) {
            .two-column {
                grid-template-columns: 1fr;
            }
            .toc-grid {
                grid-template-columns: 1fr;
            }
        }
        
        .badge {
            display: inline-block;
            padding: 2px 8px;
            border-radius: 12px;
            font-size: 12px;
            font-weight: 600;
            margin-left: 8px;
        }
        
        .badge-common {
            background: #dbeafe;
            color: #1d4ed8;
        }
        
        .badge-emergency {
            background: #fee2e2;
            color: #dc2626;
        }
        
        .badge-boards {
            background: #fef3c7;
            color: #d97706;
        }
        
        .back-to-top {
            display: inline-block;
            margin-top: 20px;
            color: #6f42c1;
            text-decoration: none;
            font-size: 14px;
        }
        
        .comparison-table th {
            background: #6f42c1;
        }
        
        .positive {
            color: #16a34a;
            font-weight: 600;
        }
        
        .negative {
            color: #dc2626;
            font-weight: 600;
        }
        
        .flowchart {
            background: #f8fafc;
            border: 2px dashed #6f42c1;
            border-radius: 8px;
            padding: 20px;
            margin: 20px 0;
            text-align: center;
        }
        
        .flowchart-step {
            background: #6f42c1;
            color: white;
            padding: 10px 20px;
            border-radius: 6px;
            display: inline-block;
            margin: 5px;
        }
        
        .flowchart-arrow {
            font-size: 24px;
            color: #6f42c1;
            margin: 0 10px;
        }
    </style>
</head>
<body>

<div class="header-box">
    <h1>ü¶¥ Rheumatology Study Guide</h1>
    <div class="subtitle">Internal Medicine Residency Preparation</div>
    <div class="subtitle" style="margin-top: 15px; font-size: 14px;">Comprehensive review of autoimmune & inflammatory conditions</div>
</div>

<div class="toc">
    <h2>üìö Table of Contents</h2>
    <div class="toc-grid">
        <div>
            <strong>Core Conditions</strong>
            <a href="#ra">1. Rheumatoid Arthritis</a>
            <a href="#sle">2. Systemic Lupus Erythematosus</a>
            <a href="#gout">3. Gout & Pseudogout</a>
            <a href="#pmr-gca">4. PMR & Giant Cell Arteritis</a>
            <a href="#spondy">5. Spondyloarthropathies</a>
            <a href="#scleroderma">6. Systemic Sclerosis</a>
        </div>
        <div>
            <strong>Advanced Topics</strong>
            <a href="#vasculitis">7. Vasculitis</a>
            <a href="#myositis">8. Inflammatory Myopathies</a>
            <a href="#aps">9. Antiphospholipid Syndrome</a>
            <a href="#sjogren">10. Sj√∂gren's Syndrome</a>
            <a href="#emergencies">11. Rheumatologic Emergencies</a>
        </div>
        <div>
            <strong>Diagnostics & Treatment</strong>
            <a href="#serologies">12. Autoantibodies & Serologies</a>
            <a href="#imaging">13. Rheumatologic Imaging</a>
            <a href="#arthrocentesis">14. Arthrocentesis & Synovial Fluid</a>
            <a href="#dmards">15. DMARDs & Biologics</a>
            <a href="#steroids">16. Glucocorticoid Management</a>
        </div>
        <div>
            <strong>Reference</strong>
            <a href="#trials">17. Landmark Trials</a>
            <a href="#criteria">18. Classification Criteria</a>
            <a href="#pearls">19. High-Yield Clinical Pearls</a>
            <a href="#boards">20. Board-Style Questions</a>
        </div>
    </div>
</div>

<!-- SECTION 1: RHEUMATOID ARTHRITIS -->
<div class="section" id="ra">
    <h2>1. Rheumatoid Arthritis <span class="badge badge-common">Common</span></h2>
    
    <h3>Epidemiology & Pathophysiology</h3>
    <ul>
        <li><strong>Prevalence:</strong> 0.5-1% of population, F:M = 3:1</li>
        <li><strong>Peak onset:</strong> 30-50 years (but can occur at any age)</li>
        <li><strong>Pathophysiology:</strong> Autoimmune synovitis ‚Üí pannus formation ‚Üí cartilage/bone destruction</li>
        <li><strong>Genetic association:</strong> HLA-DR4 (shared epitope), PTPN22</li>
        <li><strong>Environmental triggers:</strong> Smoking (strongest modifiable risk factor), periodontal disease, silica exposure</li>
    </ul>
    
    <h3>Clinical Presentation</h3>
    <div class="mnemonic-box">
        <strong>MCP/PIP/Wrist</strong> ‚Äî RA loves the small joints of hands (spares DIPs!)
    </div>
    
    <h4>Joint Involvement</h4>
    <ul>
        <li><strong>Classic pattern:</strong> Symmetric polyarthritis of small joints</li>
        <li><strong>Hands:</strong> MCP, PIP (spares DIP)</li>
        <li><strong>Wrists:</strong> Very common, early involvement</li>
        <li><strong>Feet:</strong> MTP joints</li>
        <li><strong>Other:</strong> Knees, ankles, elbows, shoulders</li>
        <li><strong>Cervical spine:</strong> C1-C2 subluxation (check before intubation!)</li>
        <li><strong>Morning stiffness:</strong> >1 hour (inflammatory pattern)</li>
    </ul>
    
    <h4>Extra-Articular Manifestations</h4>
    <table>
        <tr><th>System</th><th>Manifestation</th><th>Notes</th></tr>
        <tr><td>Skin</td><td>Rheumatoid nodules</td><td>Extensor surfaces, 20-30% of seropositive RA</td></tr>
        <tr><td>Pulmonary</td><td>ILD, pleural effusions, nodules</td><td>ILD is leading cause of RA mortality; UIP or NSIP pattern</td></tr>
        <tr><td>Cardiac</td><td>Pericarditis, accelerated atherosclerosis</td><td>CV disease is #1 cause of death in RA</td></tr>
        <tr><td>Ocular</td><td>Scleritis, episcleritis, keratoconjunctivitis sicca</td><td>Scleritis can be vision-threatening</td></tr>
        <tr><td>Hematologic</td><td>Anemia of chronic disease, Felty syndrome</td><td>Felty = RA + splenomegaly + neutropenia</td></tr>
        <tr><td>Neurologic</td><td>Carpal tunnel, cervical myelopathy</td><td>C1-C2 instability can cause cord compression</td></tr>
        <tr><td>Vascular</td><td>Rheumatoid vasculitis</td><td>Rare but serious; digital infarcts, mononeuritis multiplex</td></tr>
    </table>
    
    <div class="pearl-box">
        Felty syndrome (RA + splenomegaly + neutropenia) increases infection risk. These patients need aggressive RA treatment.
    </div>
    
    <h3>Diagnostic Workup</h3>
    <h4>Serologies</h4>
    <table>
        <tr><th>Test</th><th>Sensitivity</th><th>Specificity</th><th>Clinical Utility</th></tr>
        <tr><td>RF (Rheumatoid Factor)</td><td>70-80%</td><td>80%</td><td>Can be positive in other conditions (HCV, Sj√∂gren's, age)</td></tr>
        <tr><td>Anti-CCP (ACPA)</td><td>60-70%</td><td>95%</td><td>More specific; predicts erosive disease</td></tr>
        <tr><td>ESR/CRP</td><td>Variable</td><td>Low</td><td>Disease activity monitoring</td></tr>
    </table>
    
    <div class="pearl-box">
        Anti-CCP can be positive years before clinical RA develops. Double-positive (RF+ and anti-CCP+) predicts more aggressive, erosive disease.
    </div>
    
    <h4>Imaging</h4>
    <ul>
        <li><strong>X-ray (early):</strong> Soft tissue swelling, periarticular osteopenia, joint space narrowing</li>
        <li><strong>X-ray (late):</strong> Erosions (marginal), subluxations, deformities</li>
        <li><strong>Ultrasound:</strong> Synovitis, erosions (more sensitive than X-ray early)</li>
        <li><strong>MRI:</strong> Bone marrow edema, early erosions, synovitis</li>
    </ul>
    
    <div class="criteria-box">
        <h4>2010 ACR/EULAR Classification Criteria for RA</h4>
        <p>Score ‚â•6/10 = definite RA (requires at least 1 swollen joint)</p>
        <table>
            <tr><th>Category</th><th>Points</th></tr>
            <tr><td colspan="2"><strong>Joint Involvement</strong></td></tr>
            <tr><td>1 large joint</td><td>0</td></tr>
            <tr><td>2-10 large joints</td><td>1</td></tr>
            <tr><td>1-3 small joints</td><td>2</td></tr>
            <tr><td>4-10 small joints</td><td>3</td></tr>
            <tr><td>>10 joints (at least 1 small)</td><td>5</td></tr>
            <tr><td colspan="2"><strong>Serology</strong></td></tr>
            <tr><td>Negative RF and negative ACPA</td><td>0</td></tr>
            <tr><td>Low-positive RF or low-positive ACPA</td><td>2</td></tr>
            <tr><td>High-positive RF or high-positive ACPA</td><td>3</td></tr>
            <tr><td colspan="2"><strong>Acute Phase Reactants</strong></td></tr>
            <tr><td>Normal CRP and normal ESR</td><td>0</td></tr>
            <tr><td>Abnormal CRP or abnormal ESR</td><td>1</td></tr>
            <tr><td colspan="2"><strong>Duration of Symptoms</strong></td></tr>
            <tr><td><6 weeks</td><td>0</td></tr>
            <tr><td>‚â•6 weeks</td><td>1</td></tr>
        </table>
    </div>
    
    <h3>Treatment</h3>
    
    <h4>Treatment Goals</h4>
    <ul>
        <li><strong>Treat-to-target:</strong> Aim for remission or low disease activity</li>
        <li><strong>Window of opportunity:</strong> Early aggressive treatment prevents joint damage</li>
        <li><strong>Monitoring:</strong> DAS28, CDAI, or SDAI scores every 3-6 months</li>
    </ul>
    
    <h4>First-Line: csDMARDs</h4>
    <div class="drug-box">
        <strong>Methotrexate (MTX)</strong> ‚Äî Anchor drug for RA
        <ul>
            <li><strong>Dose:</strong> Start 7.5-15mg weekly, titrate to 20-25mg weekly</li>
            <li><strong>Folate:</strong> Folic acid 1mg daily (reduces side effects)</li>
            <li><strong>Monitoring:</strong> CBC, CMP, LFTs at baseline, then every 2-4 weeks initially, then every 8-12 weeks</li>
            <li><strong>Contraindications:</strong> Pregnancy (teratogenic), liver disease, heavy alcohol use, severe renal impairment</li>
            <li><strong>Side effects:</strong> GI upset, stomatitis, hepatotoxicity, cytopenias, pneumonitis</li>
        </ul>
    </div>
    
    <table>
        <tr><th>Drug</th><th>Mechanism</th><th>Key Monitoring</th><th>Notable Side Effects</th></tr>
        <tr><td>Methotrexate</td><td>Folate antagonist</td><td>CBC, LFTs, creatinine</td><td>Hepatotoxicity, pneumonitis</td></tr>
        <tr><td>Leflunomide</td><td>Pyrimidine synthesis inhibitor</td><td>CBC, LFTs</td><td>Hepatotoxicity, teratogenic</td></tr>
        <tr><td>Sulfasalazine</td><td>Anti-inflammatory</td><td>CBC</td><td>GI upset, rash, cytopenias</td></tr>
        <tr><td>Hydroxychloroquine</td><td>Multiple</td><td>Annual eye exam (after 5 yrs)</td><td>Retinal toxicity (rare)</td></tr>
    </table>
    
    <h4>Second-Line: Biologics & Targeted Synthetic DMARDs</h4>
    <table>
        <tr><th>Class</th><th>Drugs</th><th>Key Considerations</th></tr>
        <tr><td>TNF inhibitors</td><td>Adalimumab, Etanercept, Infliximab, Certolizumab, Golimumab</td><td>Screen for TB, Hep B; avoid in CHF, demyelinating disease</td></tr>
        <tr><td>IL-6 inhibitors</td><td>Tocilizumab, Sarilumab</td><td>Can mask infection (suppresses CRP); monitor lipids</td></tr>
        <tr><td>T-cell costimulation</td><td>Abatacept</td><td>Avoid live vaccines</td></tr>
        <tr><td>B-cell depletion</td><td>Rituximab</td><td>Screen for Hep B; infusion reactions</td></tr>
        <tr><td>JAK inhibitors</td><td>Tofacitinib, Baricitinib, Upadacitinib</td><td>VTE risk, herpes zoster risk; avoid in age >65 with CV risk</td></tr>
    </table>
    
    <div class="emergency-box">
        Before starting biologics: Screen for latent TB (PPD or IGRA), Hepatitis B (HBsAg, anti-HBc, anti-HBs), and Hepatitis C. Update vaccinations (no live vaccines on biologics).
    </div>
    
    <h3>Prognosis & Monitoring</h3>
    <ul>
        <li><strong>Poor prognostic factors:</strong> High-titer RF, anti-CCP positive, early erosions, extra-articular disease, high disease activity</li>
        <li><strong>CV risk:</strong> RA increases CV mortality 1.5-2x; treat traditional risk factors aggressively</li>
        <li><strong>Remission rates:</strong> 20-40% achieve sustained remission with modern therapy</li>
    </ul>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 2: SLE -->
<div class="section" id="sle">
    <h2>2. Systemic Lupus Erythematosus <span class="badge badge-common">Common</span> <span class="badge badge-boards">Boards Favorite</span></h2>
    
    <h3>Epidemiology</h3>
    <ul>
        <li><strong>Prevalence:</strong> 20-150 per 100,000</li>
        <li><strong>F:M ratio:</strong> 9:1 (during childbearing years)</li>
        <li><strong>Peak onset:</strong> 15-44 years</li>
        <li><strong>Higher prevalence/severity:</strong> African American, Hispanic, Asian populations</li>
    </ul>
    
    <h3>Clinical Manifestations</h3>
    <div class="mnemonic-box">
        <strong>SOAP BRAIN MD</strong> ‚Äî SLE criteria
        <ul style="columns: 2; margin-top: 10px;">
            <li><strong>S</strong>erositis</li>
            <li><strong>O</strong>ral ulcers</li>
            <li><strong>A</strong>rthritis</li>
            <li><strong>P</strong>hotosensitivity</li>
            <li><strong>B</strong>lood disorders</li>
            <li><strong>R</strong>enal disease</li>
            <li><strong>A</strong>NA</li>
            <li><strong>I</strong>mmunologic (anti-dsDNA, anti-Sm, antiphospholipid)</li>
            <li><strong>N</strong>eurologic</li>
            <li><strong>M</strong>alar rash</li>
            <li><strong>D</strong>iscoid rash</li>
        </ul>
    </div>
    
    <table>
        <tr><th>System</th><th>Manifestations</th><th>Key Points</th></tr>
        <tr><td><strong>Skin</strong></td><td>Malar rash, discoid rash, photosensitivity, oral ulcers, alopecia</td><td>Malar rash spares nasolabial folds; discoid causes scarring</td></tr>
        <tr><td><strong>Joints</strong></td><td>Non-erosive arthritis, Jaccoud's arthropathy</td><td>Unlike RA: no erosions, reducible deformities</td></tr>
        <tr><td><strong>Renal</strong></td><td>Lupus nephritis (Class I-VI)</td><td>Most important prognostic factor; proteinuria, active sediment</td></tr>
        <tr><td><strong>Hematologic</strong></td><td>Cytopenias, hemolytic anemia, lymphopenia, thrombocytopenia</td><td>Lymphopenia (<1000) correlates with disease activity</td></tr>
        <tr><td><strong>Serositis</strong></td><td>Pleuritis, pericarditis</td><td>May present as chest pain</td></tr>
        <tr><td><strong>Neurologic</strong></td><td>Seizures, psychosis, cognitive dysfunction, stroke</td><td>19 different neuropsychiatric manifestations</td></tr>
        <tr><td><strong>Cardiac</strong></td><td>Pericarditis, Libman-Sacks endocarditis, accelerated atherosclerosis</td><td>Leading cause of late death = CV disease</td></tr>
        <tr><td><strong>Pulmonary</strong></td><td>Pleuritis, ILD, shrinking lung syndrome, pulmonary HTN</td><td>Shrinking lung = diaphragmatic weakness</td></tr>
    </table>
    
    <h3>Lupus Nephritis ‚Äî Critical Topic</h3>
    <table>
        <tr><th>Class</th><th>Description</th><th>Treatment</th></tr>
        <tr><td>I</td><td>Minimal mesangial</td><td>None specific</td></tr>
        <tr><td>II</td><td>Mesangial proliferative</td><td>Conservative/low-dose immunosuppression</td></tr>
        <tr><td>III</td><td>Focal proliferative (<50% glomeruli)</td><td>Induction: MMF or Cyclophosphamide + steroids</td></tr>
        <tr><td>IV</td><td>Diffuse proliferative (‚â•50% glomeruli)</td><td>Most aggressive treatment; induction + maintenance</td></tr>
        <tr><td>V</td><td>Membranous</td><td>If nephrotic: immunosuppression</td></tr>
        <tr><td>VI</td><td>Advanced sclerosis</td><td>Supportive; prepare for RRT</td></tr>
    </table>
    
    <div class="pearl-box">
        Class IV lupus nephritis is the most common and severe form. Treatment: Induction with MMF or IV cyclophosphamide + steroids, followed by maintenance with MMF or azathioprine.
    </div>
    
    <h3>Autoantibodies in SLE</h3>
    <table>
        <tr><th>Antibody</th><th>Sensitivity</th><th>Specificity</th><th>Clinical Association</th></tr>
        <tr><td>ANA</td><td>95%+</td><td>Low</td><td>Screening test; if negative, SLE very unlikely</td></tr>
        <tr><td>Anti-dsDNA</td><td>60-70%</td><td>95%</td><td>Correlates with disease activity, lupus nephritis</td></tr>
        <tr><td>Anti-Smith (Sm)</td><td>25-30%</td><td>99%</td><td>Most specific for SLE</td></tr>
        <tr><td>Anti-Ro (SSA)</td><td>30%</td><td>Low</td><td>Neonatal lupus, congenital heart block, photosensitivity</td></tr>
        <tr><td>Anti-La (SSB)</td><td>15%</td><td>Moderate</td><td>Usually with anti-Ro; less nephritis</td></tr>
        <tr><td>Anti-RNP</td><td>30%</td><td>Low</td><td>MCTD overlap</td></tr>
        <tr><td>Antiphospholipid</td><td>30-40%</td><td>Moderate</td><td>Thrombosis, pregnancy loss</td></tr>
    </table>
    
    <div class="highlight-box">
        <strong>Anti-Ro positive pregnancy:</strong> Monitor fetal heart (weekly from 16-26 weeks) for congenital heart block. IVIG and dexamethasone may be used if block detected.
    </div>
    
    <h3>Disease Activity Monitoring</h3>
    <ul>
        <li><strong>C3/C4:</strong> Low in active disease (consumption)</li>
        <li><strong>Anti-dsDNA:</strong> Rising titers often precede flare</li>
        <li><strong>ESR:</strong> Elevated in active disease</li>
        <li><strong>CRP:</strong> Usually normal in lupus flare (elevated suggests infection)</li>
        <li><strong>Urinalysis:</strong> Active sediment (RBC casts, proteinuria) = nephritis</li>
    </ul>
    
    <div class="pearl-box">
        CRP is usually NOT elevated in SLE flares (unlike most inflammatory conditions). If CRP is high in a lupus patient, think infection first!
    </div>
    
    <h3>Treatment</h3>
    <h4>All Patients</h4>
    <ul>
        <li><strong>Hydroxychloroquine:</strong> EVERYONE with SLE (reduces flares, mortality, thrombosis, damage accrual)</li>
        <li><strong>Sun protection:</strong> Sunscreen, protective clothing</li>
        <li><strong>Cardiovascular risk reduction:</strong> Aggressive management</li>
        <li><strong>Vaccinations:</strong> Annual flu, pneumococcal (no live vaccines if immunosuppressed)</li>
    </ul>
    
    <h4>By Severity</h4>
    <table>
        <tr><th>Manifestation</th><th>Treatment</th></tr>
        <tr><td>Skin, joints (mild)</td><td>HCQ ¬± NSAIDs ¬± low-dose prednisone</td></tr>
        <tr><td>Moderate disease</td><td>Add azathioprine or methotrexate</td></tr>
        <tr><td>Nephritis (Class III/IV/V)</td><td>Induction: MMF or CYC + steroids; Maintenance: MMF or AZA</td></tr>
        <tr><td>Severe/refractory</td><td>Rituximab, belimumab, voclosporin (nephritis)</td></tr>
        <tr><td>Neuropsychiatric</td><td>High-dose steroids ¬± cyclophosphamide</td></tr>
    </table>
    
    <div class="drug-box">
        <strong>Hydroxychloroquine (HCQ)</strong> ‚Äî Foundation of SLE treatment
        <ul>
            <li><strong>Dose:</strong> 200-400mg daily (‚â§5 mg/kg/day to reduce retinal toxicity)</li>
            <li><strong>Benefits:</strong> Reduces flares by 50%, reduces damage accrual, improves survival, reduces thrombosis</li>
            <li><strong>Monitoring:</strong> Baseline eye exam, then annual after 5 years (or earlier if risk factors)</li>
            <li><strong>Safe in pregnancy</strong></li>
        </ul>
    </div>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 3: GOUT -->
<div class="section" id="gout">
    <h2>3. Gout & Pseudogout <span class="badge badge-common">Common</span></h2>
    
    <h3>Gout (Monosodium Urate Crystal Disease)</h3>
    
    <h4>Risk Factors</h4>
    <ul>
        <li><strong>Hyperuricemia causes:</strong> Underexcretion (90%) vs overproduction (10%)</li>
        <li><strong>Diet:</strong> Red meat, organ meats, shellfish, alcohol (especially beer), fructose</li>
        <li><strong>Medications:</strong> Thiazides, loop diuretics, low-dose aspirin, cyclosporine</li>
        <li><strong>Comorbidities:</strong> CKD, metabolic syndrome, obesity, HTN</li>
    </ul>
    
    <h4>Clinical Stages</h4>
    <ol>
        <li><strong>Asymptomatic hyperuricemia:</strong> No treatment indicated (most never develop gout)</li>
        <li><strong>Acute gouty arthritis:</strong> Sudden, severe monoarticular inflammation</li>
        <li><strong>Intercritical gout:</strong> Asymptomatic periods between attacks</li>
        <li><strong>Chronic tophaceous gout:</strong> Tophi, chronic arthritis, joint destruction</li>
    </ol>
    
    <h4>Acute Gout Presentation</h4>
    <ul>
        <li><strong>Classic:</strong> Podagra (1st MTP) ‚Äî 50% of first attacks</li>
        <li><strong>Character:</strong> Rapid onset (peaks 12-24h), exquisitely tender, erythema, warmth</li>
        <li><strong>Other sites:</strong> Ankle, knee, wrist, elbow</li>
        <li><strong>Triggers:</strong> Dietary indiscretion, alcohol, dehydration, surgery, illness, medication changes</li>
    </ul>
    
    <div class="pearl-box">
        Serum uric acid may be NORMAL during acute attack (consumed into crystals). Don't use acute level to rule out gout!
    </div>
    
    <h4>Diagnosis</h4>
    <div class="highlight-box">
        <strong>Gold Standard:</strong> Arthrocentesis showing negatively birefringent, needle-shaped MSU crystals under polarized light microscopy
    </div>
    
    <table>
        <tr><th>Finding</th><th>Gout (MSU)</th><th>Pseudogout (CPPD)</th></tr>
        <tr><td>Crystal shape</td><td>Needle-shaped</td><td>Rhomboid/rectangular</td></tr>
        <tr><td>Birefringence</td><td>Negative (yellow parallel)</td><td>Positive (blue parallel)</td></tr>
        <tr><td>Imaging</td><td>Erosions with overhanging edges ("rat bite")</td><td>Chondrocalcinosis</td></tr>
        <tr><td>Joint distribution</td><td>1st MTP, ankle, knee</td><td>Knee, wrist, shoulder</td></tr>
    </table>
    
    <h4>Treatment: Acute Gout</h4>
    <table>
        <tr><th>Agent</th><th>Dosing</th><th>Considerations</th></tr>
        <tr><td>NSAIDs</td><td>Indomethacin 50mg TID or Naproxen 500mg BID √ó 5-7 days</td><td>Avoid if CKD, GI bleeding, CVD</td></tr>
        <tr><td>Colchicine</td><td>1.2mg, then 0.6mg 1h later; then 0.6mg daily/BID</td><td>Best within 36h of onset; reduce dose in CKD</td></tr>
        <tr><td>Corticosteroids</td><td>Prednisone 30-40mg √ó 5 days OR intra-articular</td><td>Good for CKD, multiple comorbidities</td></tr>
        <tr><td>IL-1 inhibitors</td><td>Anakinra 100mg daily √ó 3 days</td><td>Refractory cases</td></tr>
    </table>
    
    <div class="emergency-box">
        Do NOT start or stop urate-lowering therapy (ULT) during acute attack ‚Äî can prolong/worsen flare. Treat the acute attack first.
    </div>
    
    <h4>Treatment: Chronic Gout / Urate-Lowering Therapy</h4>
    <p><strong>Indications for ULT:</strong></p>
    <ul>
        <li>‚â•2 attacks per year</li>
        <li>Tophi</li>
        <li>Chronic gouty arthritis</li>
        <li>Urate nephropathy or nephrolithiasis</li>
        <li>CKD stage ‚â•3</li>
    </ul>
    
    <table>
        <tr><th>Drug</th><th>Mechanism</th><th>Dosing</th><th>Notes</th></tr>
        <tr><td>Allopurinol</td><td>Xanthine oxidase inhibitor</td><td>Start 100mg daily, titrate to goal</td><td>Dose reduce in CKD; HLA-B*5801 screening in high-risk populations</td></tr>
        <tr><td>Febuxostat</td><td>Xanthine oxidase inhibitor</td><td>40-80mg daily</td><td>Alternative if allopurinol intolerant; avoid in CVD (CARES trial)</td></tr>
        <tr><td>Probenecid</td><td>Uricosuric</td><td>500mg BID</td><td>Requires good renal function; contraindicated in nephrolithiasis</td></tr>
        <tr><td>Pegloticase</td><td>Uricase (converts urate to allantoin)</td><td>IV q2 weeks</td><td>Refractory tophaceous gout; immunogenic</td></tr>
    </table>
    
    <p><strong>Goal:</strong> Serum urate <6 mg/dL (or <5 if tophi)</p>
    
    <div class="pearl-box">
        <strong>Allopurinol hypersensitivity syndrome (AHS):</strong> Severe DRESS-like reaction. Risk factors: CKD, HLA-B*5801 (common in Han Chinese, Korean, Thai). Start low (100mg) and go slow.
    </div>
    
    <h3>Pseudogout (CPPD Crystal Arthritis)</h3>
    <ul>
        <li><strong>Crystals:</strong> Calcium pyrophosphate dihydrate</li>
        <li><strong>Classic joints:</strong> Knee (most common), wrist, shoulder</li>
        <li><strong>Imaging:</strong> Chondrocalcinosis (cartilage calcification) on X-ray</li>
        <li><strong>Associations:</strong> Hemochromatosis, hyperparathyroidism, hypothyroidism, hypomagnesemia</li>
    </ul>
    
    <p><strong>Treatment:</strong> Same as gout (NSAIDs, colchicine, steroids). No urate-lowering equivalent exists for CPPD.</p>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 4: PMR & GCA -->
<div class="section" id="pmr-gca">
    <h2>4. Polymyalgia Rheumatica & Giant Cell Arteritis <span class="badge badge-emergency">Time-Sensitive</span></h2>
    
    <h3>Polymyalgia Rheumatica (PMR)</h3>
    
    <h4>Key Features</h4>
    <ul>
        <li><strong>Age:</strong> Almost always >50 years (peak 70-80)</li>
        <li><strong>Symptoms:</strong> Bilateral shoulder and hip girdle pain/stiffness</li>
        <li><strong>Morning stiffness:</strong> >45 minutes</li>
        <li><strong>Onset:</strong> Often sudden (patients can identify exact day)</li>
        <li><strong>Constitutional:</strong> Fatigue, malaise, low-grade fever, weight loss</li>
        <li><strong>NO true weakness:</strong> Pain limits function, but strength is normal</li>
    </ul>
    
    <div class="pearl-box">
        PMR causes pain, not weakness. If true proximal muscle weakness exists, think inflammatory myopathy and check CK.
    </div>
    
    <h4>Diagnosis</h4>
    <ul>
        <li><strong>ESR:</strong> Usually >40 mm/h (often >100)</li>
        <li><strong>CRP:</strong> Elevated</li>
        <li><strong>CK:</strong> Normal (distinguishes from myositis)</li>
        <li><strong>RF, Anti-CCP:</strong> Negative</li>
        <li><strong>Ultrasound:</strong> Bilateral subacromial/subdeltoid bursitis, biceps tenosynovitis, hip synovitis</li>
    </ul>
    
    <div class="highlight-box">
        <strong>Dramatic steroid response:</strong> Improvement within 24-72 hours of starting prednisone is virtually diagnostic. If no response, reconsider diagnosis.
    </div>
    
    <h4>Treatment</h4>
    <ul>
        <li><strong>Prednisone:</strong> 12.5-25 mg daily (NOT high-dose like GCA)</li>
        <li><strong>Taper:</strong> Slowly over 1-2 years
            <ul>
                <li>Reduce by 2.5mg every 2-4 weeks until 10mg</li>
                <li>Below 10mg: reduce by 1mg every 4-8 weeks</li>
            </ul>
        </li>
        <li><strong>Relapse:</strong> Common (30-50%), especially below 10mg</li>
        <li><strong>Steroid-sparing:</strong> Methotrexate, tocilizumab if relapsing</li>
    </ul>
    
    <h3>Giant Cell Arteritis (Temporal Arteritis)</h3>
    
    <div class="emergency-box">
        GCA is an OPHTHALMOLOGIC EMERGENCY. Untreated, can cause permanent blindness within hours to days. Start steroids IMMEDIATELY if suspected ‚Äî do not wait for biopsy.
    </div>
    
    <h4>Clinical Features</h4>
    <ul>
        <li><strong>Age:</strong> >50 years (same as PMR)</li>
        <li><strong>Headache:</strong> New-onset, often temporal</li>
        <li><strong>Scalp tenderness:</strong> Pain when combing hair</li>
        <li><strong>Jaw claudication:</strong> Pain with chewing (highly specific)</li>
        <li><strong>Visual symptoms:</strong> Amaurosis fugax, diplopia, vision loss</li>
        <li><strong>Temporal artery:</strong> Tender, thickened, nodular, decreased pulse</li>
        <li><strong>PMR symptoms:</strong> Present in 40-60% of GCA patients</li>
    </ul>
    
    <div class="mnemonic-box">
        <strong>GCA Red Flags</strong> ‚Äî JAW claudication, Amaurosis/visual changes, Headache (new)
    </div>
    
    <h4>Diagnosis</h4>
    <ul>
        <li><strong>ESR:</strong> Usually very high (>50, often >100 mm/h)</li>
        <li><strong>CRP:</strong> Elevated</li>
        <li><strong>Temporal artery biopsy:</strong> Gold standard ‚Äî granulomatous inflammation with giant cells. Get 2-3cm segment; consider bilateral. Remains positive for 2-6 weeks after starting steroids</li>
        <li><strong>Temporal artery ultrasound:</strong> "Halo sign" (hypoechoic ring) is suggestive</li>
    </ul>
    
    <h4>Treatment</h4>
    <table>
        <tr><th>Scenario</th><th>Treatment</th></tr>
        <tr><td>GCA without visual symptoms</td><td>Prednisone 40-60 mg daily (1 mg/kg)</td></tr>
        <tr><td>GCA with visual symptoms</td><td>IV methylprednisolone 1g daily √ó 3 days, then high-dose oral</td></tr>
        <tr><td>Maintenance</td><td>Slow taper over 1-2 years; add aspirin 81mg daily</td></tr>
        <tr><td>Relapsing/steroid-sparing</td><td>Tocilizumab (GiACTA trial), methotrexate</td></tr>
    </table>
    
    <div class="pearl-box">
        10-30% of PMR patients have GCA. Always ask about headache, jaw claudication, and visual symptoms at every PMR visit!
    </div>
    
    <h4>Large Vessel GCA</h4>
    <ul>
        <li>Can involve aorta and major branches</li>
        <li>Presents with arm claudication, subclavian/axillary bruits, BP discrepancy between arms</li>
        <li>Risk of aortic aneurysm/dissection ‚Äî screen with CTA or PET-CT</li>
        <li>May present without cranial symptoms (biopsy-negative)</li>
    </ul>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 5: SPONDYLOARTHROPATHIES -->
<div class="section" id="spondy">
    <h2>5. Spondyloarthropathies <span class="badge badge-boards">Boards Favorite</span></h2>
    
    <h3>Overview</h3>
    <p>Group of inflammatory arthritides sharing clinical features:</p>
    <ul>
        <li><strong>Axial involvement:</strong> Sacroiliitis, spondylitis</li>
        <li><strong>Peripheral arthritis:</strong> Asymmetric, oligoarticular</li>
        <li><strong>Enthesitis:</strong> Inflammation at tendon/ligament insertions</li>
        <li><strong>Dactylitis:</strong> "Sausage digits"</li>
        <li><strong>Extra-articular:</strong> Uveitis, psoriasis, inflammatory bowel disease</li>
        <li><strong>RF negative</strong> (seronegative arthropathies)</li>
        <li><strong>HLA-B27 association</strong></li>
    </ul>
    
    <h3>Ankylosing Spondylitis (AS)</h3>
    <h4>Clinical Features</h4>
    <ul>
        <li><strong>Demographics:</strong> Young men (20-40), M:F = 3:1</li>
        <li><strong>Cardinal symptom:</strong> Inflammatory back pain
            <ul>
                <li>Onset <40 years</li>
                <li>Insidious onset</li>
                <li>Morning stiffness >30 minutes</li>
                <li>Improves with exercise, worsens with rest</li>
                <li>Nocturnal pain (wakes from sleep)</li>
            </ul>
        </li>
        <li><strong>Sacroiliitis:</strong> Alternating buttock pain</li>
        <li><strong>Decreased spinal mobility:</strong> Positive Schober test (normal ‚â•5 cm)</li>
        <li><strong>Chest expansion:</strong> Reduced (<5 cm at nipple level)</li>
    </ul>
    
    <h4>Extra-Articular Manifestations</h4>
    <table>
        <tr><th>System</th><th>Manifestation</th><th>Frequency</th></tr>
        <tr><td>Eye</td><td>Acute anterior uveitis (AAU)</td><td>25-40%</td></tr>
        <tr><td>Cardiac</td><td>Aortic regurgitation, conduction defects</td><td>2-10%</td></tr>
        <tr><td>Pulmonary</td><td>Apical fibrosis (late)</td><td>Rare</td></tr>
        <tr><td>GI</td><td>IBD (microscopic or overt)</td><td>5-10%</td></tr>
        <tr><td>Renal</td><td>IgA nephropathy, AA amyloidosis</td><td>Rare</td></tr>
    </table>
    
    <div class="pearl-box">
        Acute anterior uveitis (AAU) is the most common extra-articular manifestation of AS. Presents with acute, unilateral red eye with pain and photophobia. HLA-B27 positive in >50% of AAU.
    </div>
    
    <h4>Imaging</h4>
    <ul>
        <li><strong>X-ray sacroiliac joints:</strong> Erosions ‚Üí sclerosis ‚Üí fusion (bilateral symmetric)</li>
        <li><strong>X-ray spine:</strong> Squaring of vertebrae, syndesmophytes, "bamboo spine" (late)</li>
        <li><strong>MRI:</strong> Bone marrow edema at sacroiliac joints (early disease before X-ray changes)</li>
    </ul>
    
    <h4>Treatment</h4>
    <ul>
        <li><strong>Exercise:</strong> Essential ‚Äî maintain spinal mobility, swimming excellent</li>
        <li><strong>NSAIDs:</strong> First-line, continuous use may slow radiographic progression</li>
        <li><strong>TNF inhibitors:</strong> Highly effective for refractory disease</li>
        <li><strong>IL-17 inhibitors:</strong> Secukinumab, ixekizumab</li>
        <li><strong>JAK inhibitors:</strong> Tofacitinib, upadacitinib (newer option)</li>
        <li><strong>csDMARDs (MTX, SSZ):</strong> NOT effective for axial disease; may help peripheral arthritis</li>
    </ul>
    
    <h3>Psoriatic Arthritis (PsA)</h3>
    <h4>Clinical Patterns</h4>
    <ol>
        <li><strong>Asymmetric oligoarthritis</strong> (most common, 30-50%)</li>
        <li><strong>Symmetric polyarthritis</strong> (RA-like, 15-25%)</li>
        <li><strong>DIP arthritis</strong> (5-10%) ‚Äî associated with nail changes</li>
        <li><strong>Spondylitis/sacroiliitis</strong> (5-20%)</li>
        <li><strong>Arthritis mutilans</strong> (<5%) ‚Äî destructive, "pencil-in-cup"</li>
    </ol>
    
    <h4>Key Features</h4>
    <ul>
        <li><strong>Dactylitis:</strong> "Sausage digit" ‚Äî entire finger/toe swollen</li>
        <li><strong>Enthesitis:</strong> Achilles tendinitis, plantar fasciitis</li>
        <li><strong>Nail changes:</strong> Pitting, onycholysis, oil spots ‚Äî correlate with DIP involvement</li>
        <li><strong>Skin:</strong> Psoriasis (skin changes may precede, follow, or be absent)</li>
    </ul>
    
    <div class="pearl-box">
        15-20% of PsA patients have no visible psoriasis. Check scalp, umbilicus, gluteal cleft, and nails carefully!
    </div>
    
    <h4>Treatment</h4>
    <table>
        <tr><th>Domain</th><th>Treatment Options</th></tr>
        <tr><td>Peripheral arthritis</td><td>MTX, leflunomide, SSZ, apremilast, TNFi, IL-17i, IL-23i, JAKi</td></tr>
        <tr><td>Axial disease</td><td>NSAIDs, TNFi, IL-17i, JAKi (NOT MTX)</td></tr>
        <tr><td>Enthesitis/dactylitis</td><td>NSAIDs, TNFi, IL-17i, IL-23i</td></tr>
        <tr><td>Skin</td><td>IL-17i, IL-23i often preferred</td></tr>
    </table>
    
    <h3>Reactive Arthritis (Formerly Reiter's Syndrome)</h3>
    <ul>
        <li><strong>Trigger:</strong> Post-infectious (GI: Salmonella, Shigella, Campylobacter, Yersinia; GU: Chlamydia)</li>
        <li><strong>Timing:</strong> 1-4 weeks after infection</li>
        <li><strong>Classic triad:</strong> Arthritis + urethritis + conjunctivitis ("can't see, can't pee, can't climb a tree")</li>
        <li><strong>Other:</strong> Keratoderma blennorrhagicum, circinate balanitis, oral ulcers</li>
        <li><strong>Treatment:</strong> NSAIDs, treat underlying infection if persistent; DMARDs for chronic</li>
    </ul>
    
    <h3>Enteropathic Arthritis</h3>
    <ul>
        <li><strong>Associated with:</strong> Crohn's disease, ulcerative colitis</li>
        <li><strong>Types:</strong>
            <ul>
                <li>Peripheral (parallels bowel activity) ‚Äî treat the gut</li>
                <li>Axial (independent of bowel activity) ‚Äî treat like AS</li>
            </ul>
        </li>
        <li><strong>Caution:</strong> NSAIDs may flare IBD; TNFi (infliximab, adalimumab) preferred</li>
    </ul>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 6: SYSTEMIC SCLEROSIS -->
<div class="section" id="scleroderma">
    <h2>6. Systemic Sclerosis (Scleroderma) <span class="badge badge-boards">Boards Favorite</span></h2>
    
    <h3>Classification</h3>
    <table>
        <tr><th>Feature</th><th>Limited Cutaneous (lcSSc)</th><th>Diffuse Cutaneous (dcSSc)</th></tr>
        <tr><td>Skin involvement</td><td>Distal to elbows/knees, face</td><td>Proximal + trunk</td></tr>
        <tr><td>Antibody</td><td>Anti-centromere (ACA)</td><td>Anti-Scl-70 (topoisomerase I)</td></tr>
        <tr><td>Course</td><td>Slowly progressive</td><td>Rapidly progressive early</td></tr>
        <tr><td>Internal organs</td><td>Late PAH, less ILD</td><td>Early ILD, renal crisis</td></tr>
        <tr><td>Prognosis</td><td>Better</td><td>Worse</td></tr>
    </table>
    
    <div class="mnemonic-box">
        <strong>CREST syndrome</strong> (limited cutaneous SSc):<br>
        <strong>C</strong>alcinosis, <strong>R</strong>aynaud's, <strong>E</strong>sophageal dysmotility, <strong>S</strong>clerodactyly, <strong>T</strong>elangiectasias
    </div>
    
    <h3>Clinical Manifestations</h3>
    <h4>Skin</h4>
    <ul>
        <li><strong>Raynaud's phenomenon:</strong> Almost universal (>95%), often first symptom</li>
        <li><strong>Skin thickening:</strong> Starts in fingers, may progress proximally</li>
        <li><strong>Digital ulcers:</strong> Painful, can become infected</li>
        <li><strong>Sclerodactyly:</strong> Tight, shiny skin on fingers</li>
        <li><strong>Calcinosis:</strong> Subcutaneous calcium deposits</li>
        <li><strong>Telangiectasias:</strong> Face, hands</li>
    </ul>
    
    <h4>GI (>90% of patients)</h4>
    <ul>
        <li><strong>Esophageal dysmotility:</strong> GERD, dysphagia, Barrett's</li>
        <li><strong>Small bowel:</strong> Malabsorption, bacterial overgrowth, pseudo-obstruction</li>
        <li><strong>Colon:</strong> Constipation, wide-mouth diverticula</li>
    </ul>
    
    <h4>Pulmonary (leading cause of death)</h4>
    <ul>
        <li><strong>ILD:</strong> More common in dcSSc, anti-Scl-70 positive</li>
        <li><strong>PAH:</strong> More common in lcSSc, anti-centromere positive</li>
        <li><strong>Screening:</strong> Annual PFTs, echocardiogram</li>
    </ul>
    
    <h4>Renal ‚Äî Scleroderma Renal Crisis (SRC)</h4>
    <div class="emergency-box">
        <strong>Scleroderma renal crisis:</strong> Acute hypertensive emergency with AKI. Occurs in 10-15% of dcSSc, often within first 4 years. Risk factors: diffuse skin disease, anti-RNA polymerase III, corticosteroid use (>15mg/day).
        <br><br>
        <strong>Treatment:</strong> ACE inhibitors (captopril) ‚Äî even if creatinine rises initially. Continue even if dialysis needed. Do NOT use calcium channel blockers initially.
    </div>
    
    <h3>Autoantibodies</h3>
    <table>
        <tr><th>Antibody</th><th>Subset</th><th>Clinical Association</th></tr>
        <tr><td>Anti-centromere (ACA)</td><td>lcSSc</td><td>PAH, less ILD, better prognosis</td></tr>
        <tr><td>Anti-Scl-70 (topoisomerase I)</td><td>dcSSc</td><td>ILD, worse prognosis</td></tr>
        <tr><td>Anti-RNA polymerase III</td><td>dcSSc</td><td>Scleroderma renal crisis, cancer association</td></tr>
        <tr><td>Anti-U3 RNP (fibrillarin)</td><td>dcSSc</td><td>PAH, skeletal muscle involvement</td></tr>
        <tr><td>Anti-PM-Scl</td><td>Overlap</td><td>Myositis overlap</td></tr>
    </table>
    
    <h3>Treatment</h3>
    <table>
        <tr><th>Manifestation</th><th>Treatment</th></tr>
        <tr><td>Raynaud's</td><td>Avoid cold, CCB (nifedipine, amlodipine), PDE5 inhibitors</td></tr>
        <tr><td>Digital ulcers</td><td>CCB, PDE5 inhibitors, prostacyclin analogs (iloprost), bosentan for prevention</td></tr>
        <tr><td>GERD</td><td>PPI (high dose), lifestyle modifications</td></tr>
        <tr><td>ILD</td><td>MMF, nintedanib, tocilizumab; rituximab for refractory</td></tr>
        <tr><td>PAH</td><td>ERA (bosentan, ambrisentan), PDE5i (sildenafil), prostacyclins</td></tr>
        <tr><td>Renal crisis</td><td>ACE inhibitor ‚Äî lifesaving!</td></tr>
        <tr><td>Skin</td><td>MTX may help early; no great options</td></tr>
    </table>
    
    <div class="pearl-box">
        Avoid corticosteroids >15mg/day in diffuse SSc ‚Äî increases risk of scleroderma renal crisis!
    </div>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 7: VASCULITIS -->
<div class="section" id="vasculitis">
    <h2>7. Vasculitis <span class="badge badge-emergency">Must-Know</span></h2>
    
    <h3>Classification by Vessel Size</h3>
    <table>
        <tr><th>Vessel Size</th><th>Diseases</th><th>Key Features</th></tr>
        <tr><td><strong>Large</strong></td><td>GCA, Takayasu</td><td>Aorta and major branches</td></tr>
        <tr><td><strong>Medium</strong></td><td>PAN, Kawasaki</td><td>Visceral arteries, aneurysms</td></tr>
        <tr><td><strong>Small (immune complex)</strong></td><td>IgA vasculitis, cryoglobulinemic</td><td>Skin, kidneys, GI</td></tr>
        <tr><td><strong>Small (ANCA-associated)</strong></td><td>GPA, MPA, EGPA</td><td>Lungs, kidneys, sinuses</td></tr>
    </table>
    
    <h3>ANCA-Associated Vasculitis (AAV)</h3>
    
    <h4>ANCA Patterns</h4>
    <table>
        <tr><th>ANCA</th><th>Target</th><th>Primary Association</th></tr>
        <tr><td>c-ANCA (cytoplasmic)</td><td>PR3 (proteinase 3)</td><td>GPA (>80%)</td></tr>
        <tr><td>p-ANCA (perinuclear)</td><td>MPO (myeloperoxidase)</td><td>MPA, EGPA</td></tr>
    </table>
    
    <h4>Granulomatosis with Polyangiitis (GPA, formerly Wegener's)</h4>
    <ul>
        <li><strong>Classic triad:</strong> Upper airway + Lower airway + Kidney</li>
        <li><strong>Upper airway:</strong> Chronic sinusitis, saddle nose deformity, subglottic stenosis</li>
        <li><strong>Lungs:</strong> Nodules (can cavitate), hemorrhage, infiltrates</li>
        <li><strong>Kidney:</strong> Pauci-immune crescentic GN (RPGN)</li>
        <li><strong>Other:</strong> Scleritis, mononeuritis multiplex</li>
        <li><strong>ANCA:</strong> PR3/c-ANCA (80-90%)</li>
    </ul>
    
    <h4>Microscopic Polyangiitis (MPA)</h4>
    <ul>
        <li><strong>Similar to GPA but:</strong> No granulomas, no upper airway disease</li>
        <li><strong>Pulmonary-renal syndrome:</strong> Diffuse alveolar hemorrhage + RPGN</li>
        <li><strong>ANCA:</strong> MPO/p-ANCA (60-70%)</li>
    </ul>
    
    <h4>Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss)</h4>
    <ul>
        <li><strong>Key feature:</strong> Asthma + eosinophilia + vasculitis</li>
        <li><strong>Phases:</strong> Allergic (asthma, rhinitis) ‚Üí Eosinophilic (infiltrates) ‚Üí Vasculitic</li>
        <li><strong>Cardiac:</strong> Eosinophilic myocarditis (leading cause of death)</li>
        <li><strong>ANCA:</strong> MPO/p-ANCA (40-60%)</li>
    </ul>
    
    <h4>AAV Treatment</h4>
    <table>
        <tr><th>Phase</th><th>Regimen</th></tr>
        <tr><td>Induction (severe)</td><td>Rituximab OR Cyclophosphamide + High-dose steroids</td></tr>
        <tr><td>Induction (non-severe)</td><td>Rituximab + reduced steroids (PEXIVAS, LoVAS)</td></tr>
        <tr><td>Maintenance</td><td>Rituximab OR Azathioprine (2+ years minimum)</td></tr>
        <tr><td>Refractory</td><td>Plasma exchange (consider in DAH, severe renal)</td></tr>
    </table>
    
    <div class="pearl-box">
        RAVE trial established rituximab as equivalent (or superior for relapsing disease) to cyclophosphamide for AAV induction. Rituximab is now preferred for many patients.
    </div>
    
    <h3>Polyarteritis Nodosa (PAN)</h3>
    <ul>
        <li><strong>Medium vessel:</strong> Aneurysms at branch points, NO glomerulonephritis (spares small vessels)</li>
        <li><strong>Features:</strong> Livedo reticularis, skin nodules, mononeuritis multiplex, testicular pain, mesenteric ischemia</li>
        <li><strong>Association:</strong> Hepatitis B (treat the HBV!)</li>
        <li><strong>ANCA:</strong> Negative</li>
        <li><strong>Imaging:</strong> Mesenteric angiography shows microaneurysms</li>
    </ul>
    
    <h3>IgA Vasculitis (Henoch-Sch√∂nlein Purpura)</h3>
    <ul>
        <li><strong>Classic:</strong> Children after URI</li>
        <li><strong>Tetrad:</strong> Palpable purpura (buttocks, legs) + arthritis + abdominal pain + nephritis</li>
        <li><strong>Usually self-limited:</strong> Supportive care, steroids for severe GI/renal</li>
    </ul>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 8: INFLAMMATORY MYOPATHIES -->
<div class="section" id="myositis">
    <h2>8. Inflammatory Myopathies</h2>
    
    <h3>Classification</h3>
    <ul>
        <li><strong>Dermatomyositis (DM)</strong></li>
        <li><strong>Polymyositis (PM)</strong></li>
        <li><strong>Immune-mediated necrotizing myopathy (IMNM)</strong></li>
        <li><strong>Inclusion body myositis (IBM)</strong></li>
        <li><strong>Antisynthetase syndrome</strong></li>
    </ul>
    
    <h3>Dermatomyositis</h3>
    <h4>Skin Findings</h4>
    <ul>
        <li><strong>Heliotrope rash:</strong> Violaceous discoloration of eyelids</li>
        <li><strong>Gottron's papules:</strong> Erythematous papules over MCP/PIP/DIP (pathognomonic)</li>
        <li><strong>Gottron's sign:</strong> Same distribution but macular</li>
        <li><strong>Shawl sign:</strong> V-neck and upper back erythema</li>
        <li><strong>Mechanic's hands:</strong> Cracked, rough skin on fingers (also antisynthetase)</li>
        <li><strong>Calcinosis:</strong> Especially in juvenile DM</li>
    </ul>
    
    <h4>Muscle Involvement</h4>
    <ul>
        <li><strong>Proximal weakness:</strong> Difficulty rising from chair, climbing stairs, lifting arms</li>
        <li><strong>Symmetric</strong></li>
        <li><strong>CK:</strong> Elevated (often 10-50√ó normal)</li>
        <li><strong>Aldolase:</strong> Also elevated</li>
    </ul>
    
    <div class="emergency-box">
        <strong>Malignancy association:</strong> DM has 3-8√ó increased cancer risk. Screen with age-appropriate cancer screening + CT chest/abdomen/pelvis. Highest risk in first 1-3 years after diagnosis.
    </div>
    
    <h3>Polymyositis</h3>
    <ul>
        <li>Similar muscle involvement as DM</li>
        <li>NO skin manifestations</li>
        <li>Rare diagnosis ‚Äî many former PM cases now reclassified as IMNM or antisynthetase</li>
    </ul>
    
    <h3>Inclusion Body Myositis</h3>
    <ul>
        <li><strong>Age:</strong> >50 years, M > F</li>
        <li><strong>Distribution:</strong> Asymmetric, involves finger flexors and quadriceps (falls, difficulty gripping)</li>
        <li><strong>CK:</strong> Normal to mildly elevated</li>
        <li><strong>Treatment:</strong> Does NOT respond to immunosuppression</li>
        <li><strong>Biopsy:</strong> Rimmed vacuoles, inclusion bodies</li>
    </ul>
    
    <div class="pearl-box">
        IBM is the most common myopathy in patients >50. Key clue: weakness of finger flexors (difficulty gripping) + quadriceps weakness + poor response to steroids.
    </div>
    
    <h3>Antisynthetase Syndrome</h3>
    <ul>
        <li><strong>Antibody:</strong> Anti-Jo-1 (most common), anti-PL-7, anti-PL-12, others</li>
        <li><strong>Classic features:</strong> Myositis + ILD + arthritis + mechanic's hands + Raynaud's + fever</li>
        <li><strong>ILD:</strong> Can be severe and progressive</li>
    </ul>
    
    <h3>Myositis-Specific Antibodies</h3>
    <table>
        <tr><th>Antibody</th><th>Association</th></tr>
        <tr><td>Anti-Jo-1</td><td>Antisynthetase syndrome, ILD</td></tr>
        <tr><td>Anti-Mi-2</td><td>Classic DM, good prognosis</td></tr>
        <tr><td>Anti-MDA5</td><td>Amyopathic DM, rapidly progressive ILD (high mortality)</td></tr>
        <tr><td>Anti-TIF1-Œ≥</td><td>DM with high cancer risk</td></tr>
        <tr><td>Anti-NXP2</td><td>DM with calcinosis, cancer risk</td></tr>
        <tr><td>Anti-SRP</td><td>IMNM, severe myopathy, cardiac involvement</td></tr>
        <tr><td>Anti-HMGCR</td><td>IMNM, statin-associated (can occur without statin)</td></tr>
    </table>
    
    <h3>Treatment</h3>
    <ul>
        <li><strong>First-line:</strong> High-dose prednisone (1mg/kg/day)</li>
        <li><strong>Steroid-sparing:</strong> Methotrexate, azathioprine</li>
        <li><strong>Refractory:</strong> IVIG, rituximab, mycophenolate</li>
        <li><strong>ILD:</strong> MMF, azathioprine, rituximab, nintedanib</li>
        <li><strong>Physical therapy:</strong> Essential for maintaining function</li>
    </ul>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 9: ANTIPHOSPHOLIPID SYNDROME -->
<div class="section" id="aps">
    <h2>9. Antiphospholipid Syndrome <span class="badge badge-boards">Boards Favorite</span></h2>
    
    <h3>Definition</h3>
    <p>Autoimmune thrombophilia characterized by arterial/venous thrombosis and/or pregnancy morbidity with persistent antiphospholipid antibodies.</p>
    
    <h3>Clinical Manifestations</h3>
    <h4>Thrombosis</h4>
    <ul>
        <li><strong>Venous (most common):</strong> DVT, PE, cerebral venous sinus thrombosis</li>
        <li><strong>Arterial:</strong> Stroke, TIA, MI (often in young patients)</li>
        <li><strong>Unusual sites:</strong> Hepatic veins (Budd-Chiari), renal, adrenal</li>
    </ul>
    
    <h4>Pregnancy Complications</h4>
    <ul>
        <li>Recurrent early miscarriages (<10 weeks)</li>
        <li>Late fetal loss (>10 weeks)</li>
        <li>Preterm delivery due to preeclampsia/placental insufficiency</li>
    </ul>
    
    <h4>Other Manifestations</h4>
    <ul>
        <li><strong>Livedo reticularis</strong></li>
        <li><strong>Thrombocytopenia</strong> (moderate, usually >50k)</li>
        <li><strong>Cardiac valve disease</strong> (Libman-Sacks endocarditis)</li>
        <li><strong>Nephropathy</strong> (thrombotic microangiopathy)</li>
    </ul>
    
    <h3>Antiphospholipid Antibodies</h3>
    <table>
        <tr><th>Test</th><th>Notes</th></tr>
        <tr><td>Lupus anticoagulant (LA)</td><td>Prolongs PTT but causes thrombosis; strongest predictor</td></tr>
        <tr><td>Anticardiolipin (aCL)</td><td>IgG and IgM; medium-high titer more significant</td></tr>
        <tr><td>Anti-Œ≤2-glycoprotein I</td><td>IgG and IgM; most specific</td></tr>
    </table>
    
    <div class="criteria-box">
        <h4>Revised Sapporo Criteria for APS</h4>
        <p>‚â•1 Clinical + ‚â•1 Laboratory criterion</p>
        <p><strong>Clinical:</strong></p>
        <ul>
            <li>Vascular thrombosis (arterial, venous, or small vessel)</li>
            <li>Pregnancy morbidity (‚â•3 early losses, ‚â•1 late loss, or preterm for preeclampsia)</li>
        </ul>
        <p><strong>Laboratory (must be positive on 2 occasions ‚â•12 weeks apart):</strong></p>
        <ul>
            <li>Lupus anticoagulant</li>
            <li>Anticardiolipin IgG or IgM (medium-high titer)</li>
            <li>Anti-Œ≤2GP1 IgG or IgM</li>
        </ul>
    </div>
    
    <div class="pearl-box">
        "Triple positive" APS (all 3 antibodies positive) has highest thrombosis and pregnancy complication risk. These patients need more aggressive management.
    </div>
    
    <h3>Treatment</h3>
    <table>
        <tr><th>Scenario</th><th>Treatment</th></tr>
        <tr><td>First venous thrombosis</td><td>Warfarin INR 2-3 (indefinite)</td></tr>
        <tr><td>Arterial thrombosis</td><td>Warfarin INR 2-3 + aspirin OR higher INR 3-4</td></tr>
        <tr><td>Recurrent thrombosis on warfarin</td><td>Higher INR target, add aspirin, or LMWH</td></tr>
        <tr><td>Pregnancy (without prior thrombosis)</td><td>Low-dose aspirin ¬± prophylactic LMWH</td></tr>
        <tr><td>Pregnancy (with prior thrombosis)</td><td>Therapeutic LMWH + low-dose aspirin</td></tr>
    </table>
    
    <div class="emergency-box">
        <strong>Do NOT use DOACs in APS</strong> ‚Äî TRAPS trial showed increased thrombosis with rivaroxaban vs warfarin in triple-positive APS. Warfarin remains standard.
    </div>
    
    <h3>Catastrophic APS (CAPS)</h3>
    <ul>
        <li><strong>Definition:</strong> ‚â•3 organs involved, develops over <1 week, small vessel thrombosis on histology</li>
        <li><strong>Mortality:</strong> 30-50% even with treatment</li>
        <li><strong>Treatment:</strong> Anticoagulation + high-dose steroids + plasma exchange + IVIG ¬± rituximab</li>
    </ul>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 10: SJOGREN'S -->
<div class="section" id="sjogren">
    <h2>10. Sj√∂gren's Syndrome</h2>
    
    <h3>Overview</h3>
    <ul>
        <li><strong>Definition:</strong> Chronic autoimmune disease targeting exocrine glands (salivary, lacrimal)</li>
        <li><strong>Demographics:</strong> F:M = 9:1, peak 40-60 years</li>
        <li><strong>Types:</strong> Primary (alone) vs Secondary (with RA, SLE, scleroderma)</li>
    </ul>
    
    <h3>Clinical Features</h3>
    <h4>Sicca Symptoms (Hallmark)</h4>
    <ul>
        <li><strong>Keratoconjunctivitis sicca:</strong> Dry eyes, gritty sensation, photosensitivity</li>
        <li><strong>Xerostomia:</strong> Dry mouth, difficulty swallowing dry foods, dental caries</li>
        <li><strong>Parotid enlargement:</strong> Bilateral, episodic</li>
    </ul>
    
    <h4>Extraglandular Manifestations</h4>
    <table>
        <tr><th>System</th><th>Manifestation</th></tr>
        <tr><td>Joints</td><td>Arthralgias, non-erosive arthritis</td></tr>
        <tr><td>Skin</td><td>Purpura, xerosis, annular erythema</td></tr>
        <tr><td>Pulmonary</td><td>ILD, bronchiectasis, lymphocytic interstitial pneumonia</td></tr>
        <tr><td>Renal</td><td>Interstitial nephritis, RTA type 1 (distal)</td></tr>
        <tr><td>Neurologic</td><td>Peripheral neuropathy, CNS involvement (rare)</td></tr>
        <tr><td>Hematologic</td><td>Leukopenia, hypergammaglobulinemia, cryoglobulinemia</td></tr>
    </table>
    
    <div class="emergency-box">
        <strong>Lymphoma risk:</strong> 5-10% lifetime risk of B-cell lymphoma (especially MALT). Monitor for persistent parotid swelling, lymphadenopathy, cryoglobulinemia.
    </div>
    
    <h3>Diagnosis</h3>
    <h4>Serologies</h4>
    <ul>
        <li><strong>Anti-Ro (SSA):</strong> 60-70% sensitive</li>
        <li><strong>Anti-La (SSB):</strong> 30-40% sensitive, usually with anti-Ro</li>
        <li><strong>RF:</strong> Positive in 50-70%</li>
        <li><strong>ANA:</strong> Positive in 80%</li>
    </ul>
    
    <h4>Objective Tests</h4>
    <ul>
        <li><strong>Schirmer test:</strong> Filter paper in eye, <5mm wetting in 5 min = abnormal</li>
        <li><strong>Ocular staining:</strong> Rose bengal, lissamine green</li>
        <li><strong>Salivary flow:</strong> Unstimulated flow <0.1mL/min abnormal</li>
        <li><strong>Minor salivary gland biopsy:</strong> Focal lymphocytic sialadenitis (focus score ‚â•1)</li>
    </ul>
    
    <h3>Treatment</h3>
    <ul>
        <li><strong>Dry eyes:</strong> Artificial tears, cyclosporine drops (Restasis), punctal plugs</li>
        <li><strong>Dry mouth:</strong> Frequent sips of water, sugar-free gum, pilocarpine, cevimeline</li>
        <li><strong>Dental care:</strong> Fluoride, regular dental visits</li>
        <li><strong>Systemic disease:</strong> HCQ for arthralgias, fatigue; immunosuppressants for severe organ involvement</li>
    </ul>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 11: RHEUMATOLOGIC EMERGENCIES -->
<div class="section" id="emergencies">
    <h2>11. Rheumatologic Emergencies <span class="badge badge-emergency">Critical</span></h2>
    
    <h3>Must-Know Emergencies</h3>
    
    <div class="emergency-box">
        <strong>1. Giant Cell Arteritis with Visual Symptoms</strong><br>
        ‚Ä¢ <strong>Risk:</strong> Permanent blindness within hours<br>
        ‚Ä¢ <strong>Action:</strong> IV methylprednisolone 1g √ó 3 days IMMEDIATELY<br>
        ‚Ä¢ <strong>Don't wait:</strong> Start steroids before biopsy
    </div>
    
    <div class="emergency-box">
        <strong>2. Scleroderma Renal Crisis</strong><br>
        ‚Ä¢ <strong>Presentation:</strong> Acute HTN + AKI in diffuse SSc<br>
        ‚Ä¢ <strong>Treatment:</strong> ACE inhibitor (captopril) ‚Äî even if creatinine rises<br>
        ‚Ä¢ <strong>Avoid:</strong> High-dose steroids precipitate SRC
    </div>
    
    <div class="emergency-box">
        <strong>3. Pulmonary-Renal Syndrome (AAV)</strong><br>
        ‚Ä¢ <strong>Presentation:</strong> Diffuse alveolar hemorrhage + RPGN<br>
        ‚Ä¢ <strong>Causes:</strong> GPA, MPA, anti-GBM disease<br>
        ‚Ä¢ <strong>Treatment:</strong> High-dose steroids + rituximab/cyclophosphamide + consider plasma exchange
    </div>
    
    <div class="emergency-box">
        <strong>4. Catastrophic Antiphospholipid Syndrome</strong><br>
        ‚Ä¢ <strong>Definition:</strong> ‚â•3 organs, <1 week, microangiopathy<br>
        ‚Ä¢ <strong>Mortality:</strong> 30-50%<br>
        ‚Ä¢ <strong>Treatment:</strong> Anticoagulation + steroids + PLEX + IVIG
    </div>
    
    <div class="emergency-box">
        <strong>5. Septic Arthritis</strong><br>
        ‚Ä¢ <strong>Action:</strong> Joint aspiration BEFORE antibiotics (unless septic shock)<br>
        ‚Ä¢ <strong>Treatment:</strong> IV antibiotics + surgical washout/drainage<br>
        ‚Ä¢ <strong>Remember:</strong> RA patients on immunosuppression at high risk
    </div>
    
    <div class="emergency-box">
        <strong>6. Cervical Spine Instability (RA)</strong><br>
        ‚Ä¢ <strong>Risk:</strong> C1-C2 subluxation ‚Üí cord compression<br>
        ‚Ä¢ <strong>Presentation:</strong> Neck pain, myelopathy, sudden death<br>
        ‚Ä¢ <strong>Action:</strong> Cervical spine imaging before intubation in severe RA
    </div>
    
    <div class="emergency-box">
        <strong>7. Anti-MDA5 Dermatomyositis with ILD</strong><br>
        ‚Ä¢ <strong>Course:</strong> Rapidly progressive ILD, often amyopathic<br>
        ‚Ä¢ <strong>Mortality:</strong> Very high if untreated<br>
        ‚Ä¢ <strong>Treatment:</strong> Aggressive triple therapy (steroids + calcineurin inhibitor + cyclophosphamide)
    </div>
    
    <h3>Drug Toxicities</h3>
    <table>
        <tr><th>Drug</th><th>Toxicity</th><th>Management</th></tr>
        <tr><td>MTX</td><td>Pneumonitis</td><td>Stop MTX, steroids if severe</td></tr>
        <tr><td>MTX</td><td>Pancytopenia</td><td>Stop MTX, leucovorin rescue</td></tr>
        <tr><td>Biologics</td><td>Serious infection/sepsis</td><td>Hold biologic, broad-spectrum antibiotics</td></tr>
        <tr><td>Cyclophosphamide</td><td>Hemorrhagic cystitis</td><td>Mesna prophylaxis, hydration</td></tr>
        <tr><td>Allopurinol</td><td>DRESS/AHS</td><td>Stop immediately, supportive care, steroids</td></tr>
        <tr><td>HCQ</td><td>Retinal toxicity</td><td>Stop HCQ, ophthalmology follow-up</td></tr>
    </table>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 12: SEROLOGIES -->
<div class="section" id="serologies">
    <h2>12. Autoantibodies & Serologies</h2>
    
    <h3>Quick Reference Table</h3>
    <table>
        <tr><th>Antibody</th><th>Primary Association</th><th>Clinical Significance</th></tr>
        <tr><td>ANA</td><td>SLE (95%+), many others</td><td>Screening; if negative, SLE unlikely</td></tr>
        <tr><td>Anti-dsDNA</td><td>SLE</td><td>Specific; correlates with nephritis and activity</td></tr>
        <tr><td>Anti-Smith</td><td>SLE</td><td>Most specific for SLE</td></tr>
        <tr><td>Anti-Ro (SSA)</td><td>Sj√∂gren's, SLE</td><td>Neonatal lupus, photosensitivity</td></tr>
        <tr><td>Anti-La (SSB)</td><td>Sj√∂gren's</td><td>Usually with anti-Ro</td></tr>
        <tr><td>Anti-RNP</td><td>MCTD, SLE</td><td>Required for MCTD diagnosis</td></tr>
        <tr><td>RF</td><td>RA (70-80%)</td><td>Also positive in Sj√∂gren's, HCV, age</td></tr>
        <tr><td>Anti-CCP</td><td>RA</td><td>Most specific; predicts erosive disease</td></tr>
        <tr><td>c-ANCA/PR3</td><td>GPA</td><td>Active disease marker</td></tr>
        <tr><td>p-ANCA/MPO</td><td>MPA, EGPA</td><td>Also drug-induced vasculitis</td></tr>
        <tr><td>Anti-centromere</td><td>Limited SSc</td><td>PAH risk</td></tr>
        <tr><td>Anti-Scl-70</td><td>Diffuse SSc</td><td>ILD risk</td></tr>
        <tr><td>Anti-Jo-1</td><td>Antisynthetase syndrome</td><td>ILD, myositis</td></tr>
        <tr><td>Anti-Mi-2</td><td>DM</td><td>Classic DM, good prognosis</td></tr>
        <tr><td>Anti-MDA5</td><td>DM</td><td>Rapidly progressive ILD</td></tr>
        <tr><td>Anti-GBM</td><td>Goodpasture's</td><td>Pulmonary-renal syndrome</td></tr>
    </table>
    
    <h3>Complement Levels</h3>
    <table>
        <tr><th>Pattern</th><th>Disease</th></tr>
        <tr><td>Low C3, Low C4</td><td>SLE (active), cryoglobulinemia</td></tr>
        <tr><td>Low C3, Normal C4</td><td>Post-strep GN, MPGN, C3 glomerulopathy</td></tr>
        <tr><td>Normal C3, Low C4</td><td>Hereditary angioedema, cryoglobulinemia</td></tr>
        <tr><td>Normal C3, Normal C4</td><td>Most other autoimmune diseases</td></tr>
    </table>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 13: IMAGING -->
<div class="section" id="imaging">
    <h2>13. Rheumatologic Imaging</h2>
    
    <h3>X-ray Findings by Disease</h3>
    <table>
        <tr><th>Disease</th><th>Classic Findings</th></tr>
        <tr><td>RA</td><td>Periarticular osteopenia, symmetric joint space narrowing, marginal erosions, subluxations</td></tr>
        <tr><td>OA</td><td>Joint space narrowing, osteophytes, subchondral sclerosis, subchondral cysts</td></tr>
        <tr><td>Gout</td><td>Erosions with overhanging edges ("rat bite"), soft tissue tophi</td></tr>
        <tr><td>Pseudogout</td><td>Chondrocalcinosis (cartilage calcification)</td></tr>
        <tr><td>PsA</td><td>Pencil-in-cup deformity, DIP involvement, asymmetric</td></tr>
        <tr><td>AS</td><td>Sacroiliitis (bilateral symmetric), bamboo spine, syndesmophytes</td></tr>
    </table>
    
    <h3>Ultrasound in Rheumatology</h3>
    <ul>
        <li><strong>Synovitis:</strong> Effusion, synovial hypertrophy, increased Doppler signal</li>
        <li><strong>Erosions:</strong> Cortical breaks (more sensitive than X-ray early)</li>
        <li><strong>Crystal disease:</strong> "Double contour sign" (gout), hyperechoic deposits</li>
        <li><strong>Enthesitis:</strong> Thickening, hypoechogenicity, Doppler signal</li>
        <li><strong>GCA:</strong> "Halo sign" around temporal artery</li>
    </ul>
    
    <h3>MRI Applications</h3>
    <ul>
        <li><strong>Sacroiliitis:</strong> Bone marrow edema before X-ray changes (early SpA)</li>
        <li><strong>RA:</strong> Synovitis, bone marrow edema, early erosions</li>
        <li><strong>Myositis:</strong> Muscle edema (STIR sequence), fatty replacement</li>
        <li><strong>Avascular necrosis:</strong> Early detection before X-ray changes</li>
    </ul>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 14: ARTHROCENTESIS -->
<div class="section" id="arthrocentesis">
    <h2>14. Arthrocentesis & Synovial Fluid Analysis</h2>
    
    <h3>Synovial Fluid Classification</h3>
    <table>
        <tr><th>Type</th><th>WBC (cells/ŒºL)</th><th>Appearance</th><th>Differential</th></tr>
        <tr><td>Normal</td><td><200</td><td>Clear, viscous</td><td>‚Äî</td></tr>
        <tr><td>Non-inflammatory</td><td>200-2,000</td><td>Clear, yellow</td><td>OA, trauma, AVN</td></tr>
        <tr><td>Inflammatory</td><td>2,000-50,000</td><td>Cloudy, yellow</td><td>RA, gout, PsA, reactive</td></tr>
        <tr><td>Septic</td><td>>50,000</td><td>Purulent</td><td>Bacterial infection</td></tr>
    </table>
    
    <div class="pearl-box">
        WBC >50,000 is concerning for septic arthritis but not definitive. Gout can also cause very high WBC counts. Always send for Gram stain and culture!
    </div>
    
    <h3>Crystal Analysis</h3>
    <table>
        <tr><th>Crystal</th><th>Shape</th><th>Birefringence</th><th>Color When Parallel to Polarizer</th></tr>
        <tr><td>MSU (gout)</td><td>Needle</td><td>Negative</td><td class="positive">Yellow</td></tr>
        <tr><td>CPPD (pseudogout)</td><td>Rhomboid</td><td>Positive</td><td class="negative">Blue</td></tr>
    </table>
    
    <div class="mnemonic-box">
        <strong>Gout = Yellow when Parallel</strong> ‚Äî "Yellow taxi PARALLEL parked" (negative birefringence)
    </div>
    
    <h3>What to Order</h3>
    <ul>
        <li><strong>Routine:</strong> Cell count with differential, Gram stain, culture</li>
        <li><strong>Crystal analysis:</strong> Polarized microscopy</li>
        <li><strong>If TB suspected:</strong> AFB smear/culture</li>
        <li><strong>If gonococcal:</strong> NAAT (more sensitive than culture)</li>
    </ul>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 15: DMARDs -->
<div class="section" id="dmards">
    <h2>15. DMARDs & Biologics</h2>
    
    <h3>Conventional Synthetic DMARDs (csDMARDs)</h3>
    <table>
        <tr><th>Drug</th><th>Mechanism</th><th>Monitoring</th><th>Key Toxicities</th></tr>
        <tr><td>Methotrexate</td><td>Folate antagonist</td><td>CBC, LFTs, Cr q8-12wk</td><td>Hepatotoxicity, pneumonitis, cytopenias</td></tr>
        <tr><td>Leflunomide</td><td>Pyrimidine synthesis inhibitor</td><td>CBC, LFTs</td><td>Hepatotoxicity, teratogenic</td></tr>
        <tr><td>Sulfasalazine</td><td>Anti-inflammatory</td><td>CBC</td><td>GI upset, rash, cytopenias</td></tr>
        <tr><td>Hydroxychloroquine</td><td>Multiple</td><td>Eye exam annually (after 5yr)</td><td>Retinal toxicity</td></tr>
        <tr><td>Azathioprine</td><td>Purine antagonist</td><td>CBC, LFTs; TPMT level</td><td>Cytopenias, hepatotoxicity</td></tr>
        <tr><td>Mycophenolate</td><td>Purine synthesis inhibitor</td><td>CBC</td><td>GI upset, cytopenias, teratogenic</td></tr>
    </table>
    
    <h3>Biologic DMARDs</h3>
    <table>
        <tr><th>Class</th><th>Drugs</th><th>Uses</th><th>Key Considerations</th></tr>
        <tr><td>TNF inhibitors</td><td>Adalimumab, Etanercept, Infliximab, Certolizumab, Golimumab</td><td>RA, SpA, PsA, IBD</td><td>TB screening, avoid in CHF, demyelinating disease</td></tr>
        <tr><td>IL-6 inhibitors</td><td>Tocilizumab, Sarilumab</td><td>RA, GCA</td><td>Masks infection (suppresses CRP), monitor lipids</td></tr>
        <tr><td>IL-17 inhibitors</td><td>Secukinumab, Ixekizumab</td><td>PsA, AS, psoriasis</td><td>May worsen IBD</td></tr>
        <tr><td>IL-23 inhibitors</td><td>Ustekinumab, Guselkumab, Risankizumab</td><td>PsA, psoriasis, IBD</td><td>Generally well-tolerated</td></tr>
        <tr><td>B-cell depletion</td><td>Rituximab</td><td>RA, AAV, SLE</td><td>Hep B screening, infusion reactions</td></tr>
        <tr><td>T-cell costimulation</td><td>Abatacept</td><td>RA</td><td>Avoid live vaccines</td></tr>
        <tr><td>IL-1 inhibitors</td><td>Anakinra, Canakinumab</td><td>Gout, autoinflammatory</td><td>Injection site reactions</td></tr>
        <tr><td>BLyS inhibitor</td><td>Belimumab</td><td>SLE</td><td>Approved for lupus nephritis</td></tr>
    </table>
    
    <h3>Targeted Synthetic DMARDs (JAK Inhibitors)</h3>
    <table>
        <tr><th>Drug</th><th>JAK Selectivity</th><th>Black Box Warnings</th></tr>
        <tr><td>Tofacitinib</td><td>JAK1, JAK3</td><td>VTE, serious infections, malignancy, CV events</td></tr>
        <tr><td>Baricitinib</td><td>JAK1, JAK2</td><td>Same as above</td></tr>
        <tr><td>Upadacitinib</td><td>JAK1 selective</td><td>Same as above</td></tr>
    </table>
    
    <div class="highlight-box">
        <strong>Pre-biologic Checklist:</strong>
        <ul>
            <li>TB screening (IGRA or PPD)</li>
            <li>Hepatitis B serology (HBsAg, anti-HBc, anti-HBs)</li>
            <li>Hepatitis C antibody</li>
            <li>Update vaccinations (pneumococcal, influenza, Shingrix)</li>
            <li>No live vaccines while on biologics</li>
        </ul>
    </div>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 16: STEROIDS -->
<div class="section" id="steroids">
    <h2>16. Glucocorticoid Management</h2>
    
    <h3>Equivalent Doses</h3>
    <table>
        <tr><th>Drug</th><th>Equivalent Dose</th><th>Duration</th><th>Mineralocorticoid Effect</th></tr>
        <tr><td>Hydrocortisone</td><td>20 mg</td><td>Short</td><td>++</td></tr>
        <tr><td>Prednisone</td><td>5 mg</td><td>Intermediate</td><td>+</td></tr>
        <tr><td>Methylprednisolone</td><td>4 mg</td><td>Intermediate</td><td>+</td></tr>
        <tr><td>Dexamethasone</td><td>0.75 mg</td><td>Long</td><td>0</td></tr>
    </table>
    
    <h3>Side Effects by Duration</h3>
    <h4>Short-term (days-weeks)</h4>
    <ul>
        <li>Hyperglycemia</li>
        <li>Insomnia, mood changes</li>
        <li>Fluid retention</li>
        <li>Increased appetite</li>
    </ul>
    
    <h4>Long-term (months-years)</h4>
    <ul>
        <li><strong>Metabolic:</strong> Cushingoid features, weight gain, diabetes</li>
        <li><strong>Bone:</strong> Osteoporosis, avascular necrosis</li>
        <li><strong>Infection:</strong> Increased risk of opportunistic infections</li>
        <li><strong>Cardiovascular:</strong> HTN, dyslipidemia</li>
        <li><strong>Ocular:</strong> Cataracts, glaucoma</li>
        <li><strong>GI:</strong> PUD (especially with NSAIDs)</li>
        <li><strong>Skin:</strong> Thin skin, easy bruising</li>
        <li><strong>Adrenal:</strong> HPA axis suppression</li>
    </ul>
    
    <h3>Prophylaxis for Chronic Steroids</h3>
    <table>
        <tr><th>Indication</th><th>Intervention</th></tr>
        <tr><td>Bone protection (if prednisone ‚â•2.5mg √ó ‚â•3 months)</td><td>Calcium 1000-1200mg + Vitamin D 800-1000 IU daily; DEXA; consider bisphosphonate</td></tr>
        <tr><td>GI protection</td><td>PPI if on NSAIDs or high-risk</td></tr>
        <tr><td>PJP prophylaxis</td><td>TMP-SMX if high-dose/prolonged (>20mg √ó >1 month, especially with other immunosuppression)</td></tr>
        <tr><td>Vaccinations</td><td>Pneumococcal, influenza annually</td></tr>
    </table>
    
    <h3>Tapering Principles</h3>
    <ul>
        <li><strong>Risk of HPA suppression:</strong> >20mg/day for >3 weeks</li>
        <li><strong>Slow taper:</strong> Reduce by 10-20% every 1-2 weeks</li>
        <li><strong>Monitor for flare:</strong> Symptoms and inflammatory markers</li>
        <li><strong>Stress dosing:</strong> May need increased dose during surgery/illness if HPA suppressed</li>
    </ul>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 17: LANDMARK TRIALS -->
<div class="section" id="trials">
    <h2>17. Landmark Trials</h2>
    
    <h3>Rheumatoid Arthritis</h3>
    <table>
        <tr><th>Trial</th><th>Finding</th></tr>
        <tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20131255/" target="_blank" class="trial-link">TICORA</a></td><td>Treat-to-target improves outcomes in RA</td></tr>
        <tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27794714/" target="_blank" class="trial-link">RA-BEAM</a></td><td>Baricitinib superior to adalimumab in MTX-IR patients</td></tr>
        <tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35081281/" target="_blank" class="trial-link">ORAL Surveillance</a></td><td>Tofacitinib CV and cancer risks vs TNFi (led to black box)</td></tr>
    </table>
    
    <h3>Lupus</h3>
    <table>
        <tr><th>Trial</th><th>Finding</th></tr>
        <tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16192477/" target="_blank" class="trial-link">ALMS</a></td><td>MMF non-inferior to cyclophosphamide for lupus nephritis induction</td></tr>
        <tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33045428/" target="_blank" class="trial-link">BLISS-LN</a></td><td>Belimumab + standard of care improves lupus nephritis outcomes</td></tr>
        <tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33471988/" target="_blank" class="trial-link">AURORA</a></td><td>Voclosporin added to MMF improves lupus nephritis response</td></tr>
    </table>
    
    <h3>Vasculitis</h3>
    <table>
        <tr><th>Trial</th><th>Finding</th></tr>
        <tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20647199/" target="_blank" class="trial-link">RAVE</a></td><td>Rituximab non-inferior to cyclophosphamide for AAV; superior for relapsing disease</td></tr>
        <tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30612116/" target="_blank" class="trial-link">PEXIVAS</a></td><td>Reduced-dose steroids non-inferior in AAV; plasma exchange no benefit for most</td></tr>
        <tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28494235/" target="_blank" class="trial-link">GiACTA</a></td><td>Tocilizumab effective for GCA, allows lower steroid doses</td></tr>
    </table>
    
    <h3>Gout</h3>
    <table>
        <tr><th>Trial</th><th>Finding</th></tr>
        <tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29530634/" target="_blank" class="trial-link">CARES</a></td><td>Febuxostat associated with higher CV mortality than allopurinol</td></tr>
        <tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28614753/" target="_blank" class="trial-link">FAST</a></td><td>Febuxostat non-inferior to allopurinol for CV outcomes (conflicting with CARES)</td></tr>
    </table>
    
    <h3>Antiphospholipid Syndrome</h3>
    <table>
        <tr><th>Trial</th><th>Finding</th></tr>
        <tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30580552/" target="_blank" class="trial-link">TRAPS</a></td><td>Rivaroxaban inferior to warfarin in triple-positive APS ‚Äî stopped early</td></tr>
    </table>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 18: CLASSIFICATION CRITERIA -->
<div class="section" id="criteria">
    <h2>18. Classification Criteria Quick Reference</h2>
    
    <h3>Key Points About Classification vs Diagnosis</h3>
    <ul>
        <li>Classification criteria are designed for research, not diagnosis</li>
        <li>Clinicians can diagnose disease even if criteria not fully met</li>
        <li>But criteria are useful frameworks for clinical reasoning</li>
    </ul>
    
    <h3>Summary of Major Criteria</h3>
    <table>
        <tr><th>Disease</th><th>Key Criteria Elements</th></tr>
        <tr><td>RA (2010 ACR/EULAR)</td><td>‚â•6/10 points: joints involved, serology, APR, duration</td></tr>
        <tr><td>SLE (2019 ACR/EULAR)</td><td>ANA ‚â•1:80 as entry + ‚â•10 points from clinical/immunologic domains</td></tr>
        <tr><td>SSc (2013 ACR/EULAR)</td><td>‚â•9 points: skin thickening, fingertip lesions, telangiectasia, Raynaud's, antibodies, PAH/ILD</td></tr>
        <tr><td>PMR (2012 ACR/EULAR)</td><td>Age ‚â•50 + bilateral shoulder pain + elevated ESR/CRP + scoring system</td></tr>
        <tr><td>Gout (2015 ACR/EULAR)</td><td>‚â•8 points: clinical, lab, imaging findings; or proven crystals</td></tr>
        <tr><td>Axial SpA (ASAS)</td><td>Sacroiliitis on imaging + ‚â•1 SpA feature OR HLA-B27 + ‚â•2 SpA features</td></tr>
        <tr><td>GPA/EGPA/MPA</td><td>2022 ACR/EULAR criteria (score-based with clinical and lab findings)</td></tr>
    </table>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 19: CLINICAL PEARLS -->
<div class="section" id="pearls">
    <h2>19. High-Yield Clinical Pearls</h2>
    
    <h3>Diagnostic Pearls</h3>
    <ul>
        <li>üíé <strong>Negative ANA essentially rules out SLE</strong> ‚Äî sensitivity >95%</li>
        <li>üíé <strong>CRP usually normal in SLE flares</strong> ‚Äî if elevated, think infection</li>
        <li>üíé <strong>Uric acid can be normal during gout attack</strong> ‚Äî don't use to rule out</li>
        <li>üíé <strong>DIP involvement:</strong> OA or PsA, NOT RA</li>
        <li>üíé <strong>Morning stiffness >1 hour:</strong> inflammatory arthritis; <30 min: mechanical</li>
        <li>üíé <strong>Normal CK:</strong> PMR, NOT myositis</li>
        <li>üíé <strong>Jaw claudication:</strong> highly specific for GCA</li>
    </ul>
    
    <h3>Treatment Pearls</h3>
    <ul>
        <li>üíé <strong>Start steroids immediately for suspected GCA</strong> ‚Äî don't wait for biopsy</li>
        <li>üíé <strong>ACE inhibitors for scleroderma renal crisis</strong> ‚Äî even if Cr rises</li>
        <li>üíé <strong>Don't start/stop ULT during acute gout attack</strong></li>
        <li>üíé <strong>HCQ for everyone with SLE</strong> ‚Äî reduces flares and mortality</li>
        <li>üíé <strong>Warfarin (not DOACs) for APS</strong> ‚Äî TRAPS trial</li>
        <li>üíé <strong>MTX doesn't work for axial SpA</strong> ‚Äî use biologics</li>
        <li>üíé <strong>Rituximab = preferred for relapsing AAV</strong> ‚Äî RAVE trial</li>
    </ul>
    
    <h3>Safety Pearls</h3>
    <ul>
        <li>üíé <strong>Screen for TB before starting biologics</strong></li>
        <li>üíé <strong>HLA-B*5801 testing before allopurinol</strong> in high-risk populations</li>
        <li>üíé <strong>Eye exam for HCQ</strong> ‚Äî baseline, then annually after 5 years</li>
        <li>üíé <strong>Check TPMT before azathioprine</strong></li>
        <li>üíé <strong>Avoid steroids >15mg in diffuse SSc</strong> ‚Äî precipitates renal crisis</li>
        <li>üíé <strong>C-spine imaging before intubating severe RA patients</strong></li>
    </ul>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- SECTION 20: BOARD QUESTIONS -->
<div class="section" id="boards">
    <h2>20. Board-Style Practice Questions</h2>
    
    <h4>Question 1</h4>
    <p>A 55-year-old woman presents with 3 months of bilateral shoulder and hip pain with morning stiffness lasting 2 hours. ESR is 85 mm/h. She reports new headaches for 1 week. What is the next best step?</p>
    <p><strong>Answer:</strong> Start high-dose prednisone (40-60mg) immediately and arrange temporal artery biopsy. The new headache in a PMR patient suggests possible GCA ‚Äî a medical emergency that can cause irreversible vision loss.</p>
    
    <h4>Question 2</h4>
    <p>A 35-year-old man with a 5-year history of inflammatory back pain presents with acute, painful red eye. What is the most likely diagnosis and what is the expected HLA finding?</p>
    <p><strong>Answer:</strong> Acute anterior uveitis in the setting of ankylosing spondylitis. HLA-B27 would be expected positive in >90% of AS patients and >50% of isolated AAU cases.</p>
    
    <h4>Question 3</h4>
    <p>A 28-year-old woman with SLE and positive antiphospholipid antibodies has her first DVT. What is the recommended anticoagulation?</p>
    <p><strong>Answer:</strong> Warfarin with INR target 2-3, indefinitely. DOACs should NOT be used in APS (TRAPS trial showed increased thrombosis with rivaroxaban).</p>
    
    <h4>Question 4</h4>
    <p>A patient with diffuse cutaneous systemic sclerosis develops acute hypertension (BP 210/120) and AKI. What is the diagnosis and first-line treatment?</p>
    <p><strong>Answer:</strong> Scleroderma renal crisis. First-line treatment is ACE inhibitor (captopril), even if creatinine continues to rise initially.</p>
    
    <h4>Question 5</h4>
    <p>A 65-year-old man has acute monoarthritis of the first MTP joint. Serum uric acid is 6.2 mg/dL (normal). Does this rule out gout?</p>
    <p><strong>Answer:</strong> No. Serum uric acid can be normal during acute gout attacks. The gold standard diagnosis is arthrocentesis showing negatively birefringent, needle-shaped monosodium urate crystals.</p>
    
    <h4>Question 6</h4>
    <p>A patient with GPA (granulomatosis with polyangiitis) has pulmonary hemorrhage and RPGN. What is the recommended induction therapy?</p>
    <p><strong>Answer:</strong> High-dose IV methylprednisolone + rituximab (or cyclophosphamide). Consider plasma exchange for severe pulmonary hemorrhage or dialysis-dependent renal failure.</p>
    
    <a href="#" class="back-to-top">‚Üë Back to Table of Contents</a>
</div>

<!-- FOOTER -->
<div style="background: #f6f8fa; padding: 20px; border-radius: 8px; margin-top: 40px; text-align: center;">
    <p style="margin: 0; color: #586069; font-size: 14px;"><strong>Rheumatology Study Guide</strong></p>
    <p style="margin: 5px 0 0; color: #586069; font-size: 12px;">Internal Medicine Residency Preparation</p>
    <p style="margin: 10px 0 0; color: #6f42c1; font-size: 12px; font-weight: 600;">Version 1.0 | December 2024</p>
    <p style="margin: 10px 0 0; color: #999; font-size: 11px;">For educational purposes only. Always use clinical judgment and consult current guidelines.</p>
</div>

</body>
</html>
